<p>AbbVie（紐約證券交易所：ABBV - 獲取免費報告）在週五上午發佈了其 2024 年第二季度盈利指引的更新。公司為該時期提供了每股盈利指引為 2.530-2.570，而共識每股盈利預估為 3.050。公司發佈了營收指引為-。AbbVie 還將其 2024 財年指引更新為 10.610-10.810 美元每股盈利。</p>
<h2>AbbVie 股價上漲 1.3%</h2>
<ul>
<li>AbbVie 股票：投資者購買的絕佳機會</li>
</ul>
<p>AbbVie 股票在週五午間交易中上漲了 2.16 美元，達到 166.00 美元。該股交易量為 993,954 股，相比其平均交易量 5,621,344 股。公司的 50 天簡單移動平均線為 164.43 美元，200 天簡單移動平均線為 167.77 美元。公司市值為 2931.3 億美元，市盈率為 48.89，PEG 比為 2.10，β值為 0.64。AbbVie 的 12 個月最低價為 132.70 美元，最高價為 182.89 美元。公司的資產負債比為 7.93，流動比率為 0.94，速動比率為 0.83。</p>
<p>AbbVie（紐約證券交易所：ABBV - 獲取免費報告）上次發佈季度盈利數據是在 5 月 3 日週五。公司報告該季度每股盈利為 2.31 美元，超過每股盈利預估 2.26 美元 0.05 美元。該季度公司營收為 123.1 億美元，相比共識預估的 119.3 億美元。AbbVie 的淨利潤率為 11.02%，淨資產回報率為 179.47%。公司營收同比增長 0.7%。在去年同期的同一季度，公司每股盈利為 2.46 美元。股票分析師預計 AbbVie 在本財年將發佈 11.27 美元的每股盈利。</p>
<h2>AbbVie 股息公告</h2>
<ul>
<li>投資生物科技：高風險可能帶來高回報</li>
</ul>
<p>該公司最近宣佈每季度股息，將於 8 月 15 日星期四支付。截至 7 月 15 日星期一持股人將獲得每股 1.55 美元的股息。除息日為 7 月 15 日星期一。這代表年化基礎上的 6.20 美元股息和 3.73% 的股息率。AbbVie 的派息比率為 183.98%。</p>
<h2>分析師升級和降級</h2>
<p>幾位股票研究分析師對該股發表了評論。BMO Capital Markets 將 AbbVie 的目標股價從 195.00 美元降至 180.00 美元，並在 4 月 29 日星期一的研究報告中為該公司設定了超買評級。巴克萊將 AbbVie 的價格目標從 195.00 美元降至 187.00 美元，並在 4 月 29 日星期一的研究報告中為該公司設定了超重評級。Piper Sandler Companies 重申了對 AbbVie 的超買評級，並在週三的研究報告中設定了 190.00 美元的價格目標。Cantor Fitzgerald 重申了對 AbbVie 的超買評級，並在 6 月 20 日星期四的研究報告中設定了 200.00 美元的價格目標。最後，Guggenheim 將 AbbVie 的目標股價從 188.00 美元上調至 190.00 美元，並在 3 月 22 日星期五的報告中為該股設定了買入評級。兩位股票研究分析師對該股進行了持有評級，十二位發出了買入評級，一位給予該公司強烈買入評級。根據 MarketBeat.com 的數據，AbbVie 目前的共識評級為中等買入，平均目標股價為 181.07 美元。</p>
<ul>
<li>兩家增長潛力巨大的仿製藥製造商</li>
</ul>
<p><strong>閲讀我們關於 ABBV 的最新股票分析</strong></p>
<h2>關於 AbbVie（獲取免費報告）</h2>
<p>AbbVie Inc 在全球範圍內發現、開發、生產和銷售藥品。公司提供 Humira，用於治療自身免疫和腸道貝赫切特病以及膿皰病；Skyrizi 用於治療中度至重度斑塊狀銀屑病、銀屑病和克羅恩病；Rinvoq 用於治療類風濕和銀屑病性關節炎、強直性脊柱炎、特應性皮炎、軸突關節病、潰瘍性結腸炎和克羅恩病；Imbruvica 用於治療成人血液癌症患者；Epkinly 用於治療淋巴瘤；Elahere 用於治療癌症；Venclexta/Venclyxto 用於治療血液癌症。</p>
<h2>精選故事</h2>
<ul>
<li>我們比 AbbVie 更喜歡的五隻股票</li>
<li>如何投資保險公司：指南</li>
<li>星座品牌股票 2025 年第一季度：擊敗安海斯 - 布希？</li>
<li>如何投資 FAANG 股票</li>
<li>高通股票在負面新聞面前持續上漲</li>
<li>股票板塊對成功投資的重要性</li>
<li>具有穩定增長機會的前三隻夏季股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 揭示：3 CENT 加密貨幣將於 6 月 24 日爆發？（來自 True Market Insiders）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NDgz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NDgz"/></p>
<h2>您現在是否應該投資 1000 美元購買 AbbVie 股票？</h2>
<p>在考慮 AbbVie 之前，您可能希望聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂尖和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 AbbVie 不在名單上。</p>
<p>儘管 AbbVie 目前在分析師中有 “中等買入” 評級，但頂級分析師認為這五隻股票是更好的選擇。</p>
<p>查看這五隻股票</p>

艾伯維

<p>AbbVie 更新了其 2024 年第二季度收益預測，提供了每股收益指導範圍為 2.530-2.570，而市場普遍預期為 3.050。該公司還將其 2024 年全年指導範圍更新為每股收益 10.610-10.810。在公告後，AbbVie 股票上漲了 1.3%</p>

<p>AbbVie (NYSE:ABBV - Get Free Report) issued an update on its second quarter 2024 earnings guidance on Friday morning. The company provided earnings per share guidance of 2.530-2.570 for the period, compared to the consensus earnings per share estimate of 3.050. The company issued revenue guidance of -. AbbVie also updated its FY 2024 guidance to 10.610-10.810 EPS.</p>
<div class="lb-trans"><p>AbbVie（紐約證券交易所：ABBV - 獲取免費報告）在週五上午發佈了其 2024 年第二季度盈利指引的更新。公司為該時期提供了每股盈利指引為 2.530-2.570，而共識每股盈利預估為 3.050。公司發佈了營收指引為-。AbbVie 還將其 2024 財年指引更新為 10.610-10.810 美元每股盈利。</p>
</div><h2>AbbVie Trading Up 1.3 %</h2>
<ul>
<li>AbbVie Stock: A Perfect Dip for Investors to Buy</li>
</ul>
<div class="lb-trans"><h2>AbbVie 股價上漲 1.3%</h2>
<ul>
<li>AbbVie 股票：投資者購買的絕佳機會</li>
</ul>
</div><p>AbbVie stock traded up $2.16 during midday trading on Friday, reaching $166.00. The stock had a trading volume of 993,954 shares, compared to its average volume of 5,621,344. The firm's fifty day simple moving average is $164.43 and its two-hundred day simple moving average is $167.77. The firm has a market cap of $293.13 billion, a price-to-earnings ratio of 48.89, a PEG ratio of 2.10 and a beta of 0.64. AbbVie has a twelve month low of $132.70 and a twelve month high of $182.89. The company has a debt-to-equity ratio of 7.93, a current ratio of 0.94 and a quick ratio of 0.83.</p>
<div class="lb-trans"><p>AbbVie 股票在週五午間交易中上漲了 2.16 美元，達到 166.00 美元。該股交易量為 993,954 股，相比其平均交易量 5,621,344 股。公司的 50 天簡單移動平均線為 164.43 美元，200 天簡單移動平均線為 167.77 美元。公司市值為 2931.3 億美元，市盈率為 48.89，PEG 比為 2.10，β值為 0.64。AbbVie 的 12 個月最低價為 132.70 美元，最高價為 182.89 美元。公司的資產負債比為 7.93，流動比率為 0.94，速動比率為 0.83。</p>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Friday, May 3rd. The company reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.26 by $0.05. The company had revenue of $12.31 billion for the quarter, compared to the consensus estimate of $11.93 billion. AbbVie had a net margin of 11.02% and a return on equity of 179.47%. The business's revenue was up .7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.46 EPS. Equities analysts anticipate that AbbVie will post 11.27 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>AbbVie（紐約證券交易所：ABBV - 獲取免費報告）上次發佈季度盈利數據是在 5 月 3 日週五。公司報告該季度每股盈利為 2.31 美元，超過每股盈利預估 2.26 美元 0.05 美元。該季度公司營收為 123.1 億美元，相比共識預估的 119.3 億美元。AbbVie 的淨利潤率為 11.02%，淨資產回報率為 179.47%。公司營收同比增長 0.7%。在去年同期的同一季度，公司每股盈利為 2.46 美元。股票分析師預計 AbbVie 在本財年將發佈 11.27 美元的每股盈利。</p>
</div><h2>AbbVie Dividend Announcement</h2>
<ul>
<li>Investing in Biotech: High Risk for a Potentially High Reward</li>
</ul>
<div class="lb-trans"><h2>AbbVie 股息公告</h2>
<ul>
<li>投資生物科技：高風險可能帶來高回報</li>
</ul>
</div><p>The business also recently announced a quarterly dividend, which will be paid on Thursday, August 15th. Stockholders of record on Monday, July 15th will be given a dividend of $1.55 per share. The ex-dividend date is Monday, July 15th. This represents a $6.20 dividend on an annualized basis and a dividend yield of 3.73%. AbbVie's payout ratio is 183.98%.</p>
<div class="lb-trans"><p>該公司最近宣佈每季度股息，將於 8 月 15 日星期四支付。截至 7 月 15 日星期一持股人將獲得每股 1.55 美元的股息。除息日為 7 月 15 日星期一。這代表年化基礎上的 6.20 美元股息和 3.73% 的股息率。AbbVie 的派息比率為 183.98%。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師升級和降級</h2>
</div><p>Several equities research analysts have commented on the stock. BMO Capital Markets lowered their target price on shares of AbbVie from $195.00 to $180.00 and set an outperform rating for the company in a research note on Monday, April 29th. Barclays lowered their price objective on shares of AbbVie from $195.00 to $187.00 and set an overweight rating for the company in a research report on Monday, April 29th. Piper Sandler Companies reissued an overweight rating and set a $190.00 price objective on shares of AbbVie in a research report on Wednesday. Cantor Fitzgerald reissued an overweight rating and set a $200.00 price objective on shares of AbbVie in a research report on Thursday, June 20th. Finally, Guggenheim increased their target price on shares of AbbVie from $188.00 to $190.00 and gave the stock a buy rating in a report on Friday, March 22nd. Two equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, AbbVie presently has a consensus rating of Moderate Buy and an average price target of $181.07.</p>
<ul>
<li>2 Generic Drug Makers With Growing Runways</li>
</ul>
<div class="lb-trans"><p>幾位股票研究分析師對該股發表了評論。BMO Capital Markets 將 AbbVie 的目標股價從 195.00 美元降至 180.00 美元，並在 4 月 29 日星期一的研究報告中為該公司設定了超買評級。巴克萊將 AbbVie 的價格目標從 195.00 美元降至 187.00 美元，並在 4 月 29 日星期一的研究報告中為該公司設定了超重評級。Piper Sandler Companies 重申了對 AbbVie 的超買評級，並在週三的研究報告中設定了 190.00 美元的價格目標。Cantor Fitzgerald 重申了對 AbbVie 的超買評級，並在 6 月 20 日星期四的研究報告中設定了 200.00 美元的價格目標。最後，Guggenheim 將 AbbVie 的目標股價從 188.00 美元上調至 190.00 美元，並在 3 月 22 日星期五的報告中為該股設定了買入評級。兩位股票研究分析師對該股進行了持有評級，十二位發出了買入評級，一位給予該公司強烈買入評級。根據 MarketBeat.com 的數據，AbbVie 目前的共識評級為中等買入，平均目標股價為 181.07 美元。</p>
<ul>
<li>兩家增長潛力巨大的仿製藥製造商</li>
</ul>
</div><p><strong>Read Our Latest Stock Analysis on ABBV</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 ABBV 的最新股票分析</strong></p>
</div><h2>About AbbVie (Get Free Report)</h2>
<div class="lb-trans"><h2>關於 AbbVie（獲取免費報告）</h2>
</div><p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>AbbVie Inc 在全球範圍內發現、開發、生產和銷售藥品。公司提供 Humira，用於治療自身免疫和腸道貝赫切特病以及膿皰病；Skyrizi 用於治療中度至重度斑塊狀銀屑病、銀屑病和克羅恩病；Rinvoq 用於治療類風濕和銀屑病性關節炎、強直性脊柱炎、特應性皮炎、軸突關節病、潰瘍性結腸炎和克羅恩病；Imbruvica 用於治療成人血液癌症患者；Epkinly 用於治療淋巴瘤；Elahere 用於治療癌症；Venclexta/Venclyxto 用於治療血液癌症。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than AbbVie</li>
<li>How to Invest in Insurance Companies: A Guide</li>
<li>Constellation Brands Stock Q1 2025: Crushing Anheuser-Busch?</li>
<li>How to Invest in the FAANG Stocks</li>
<li>Qualcomm Stock Continues to Rise in the Face of Negative News</li>
<li>Why Are Stock Sectors Important to Successful Investing?</li>
<li>Top 3 Summer Stocks with Solid Growth Opportunities</li>
</ul>
<div class="lb-trans"><h2>精選故事</h2>
<ul>
<li>我們比 AbbVie 更喜歡的五隻股票</li>
<li>如何投資保險公司：指南</li>
<li>星座品牌股票 2025 年第一季度：擊敗安海斯 - 布希？</li>
<li>如何投資 FAANG 股票</li>
<li>高通股票在負面新聞面前持續上漲</li>
<li>股票板塊對成功投資的重要性</li>
<li>具有穩定增長機會的前三隻夏季股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ Exposed: 3 CENT Crypto to Explode June 24th? (From True Market Insiders)(Ad)</p>
<div class="lb-trans"><p>→ 揭示：3 CENT 加密貨幣將於 6 月 24 日爆發？（來自 True Market Insiders）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NDgz" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8483&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in AbbVie right now?</h2>
<div class="lb-trans"><h2>您現在是否應該投資 1000 美元購買 AbbVie 股票？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 AbbVie 之前，您可能希望聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂尖和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 AbbVie 不在名單上。</p>
</div><p>While AbbVie currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 AbbVie 目前在分析師中有 “中等買入” 評級，但頂級分析師認為這五隻股票是更好的選擇。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

艾伯維（NYSE:ABBV）發佈 2024 年第二季度收益預期